Dr. Mary L. O’Connor Leppert, MB, BCh, is a member of the medical staff in the department of Neurodevelopmental Medicine. Dr. Leppert is the director of the Center for Development and Learning and is the co-director of the Infant Neurodevelopment Center. She is a consultant physician at St. Agnes Hospital, and an associate professor of Pediatrics at The Johns Hopkins University School of Medicine.
Dr. Leppert received her undergraduate degree in biology from the Catholic University of America in Washington, DC. She received her medical training at the national Universities of Ireland, University College Cork, where she earned her M.B., B.Ch., B.A.O. degrees. She completed a residency in pediatrics at St. Agnes Hospital in Baltimore MD, and joined Kennedy Krieger in 1992 with a fellowship in developmental pediatrics through the Johns Hopkins University School of Medicine. She has been an active medical staff member at the Kennedy Krieger Institute since 1995 in the division of Neurology and Developmental Medicine. Dr. Leppert is also currently a pediatrician at the Johns Hopkins Hospital as well as an assistant professor of pediatrics at the Johns Hopkins University School of Medicine. Dr. Leppert has an active role in the education of the residents and fellows of the Neurodevelopmental Disabilities Residency Program.
Dr. Leppert’s interests include the early identification of developmental disorders, the understanding of the cause of developmental disorders, and the education of trainees on early identification of developmental disorders and associated deficits. She was part of a multicenter study to standardize the Capute Scales of Development, and the NICU follow up clinic is involved with several neonatal and preschool outcome studies. Dr. Leppert’s educational focus surrounds curriculum development and dissemination of training on early identification and co-occurring disorders in early childhood.
McCurdy M, Bellows A, Deng D, Leppert M, Mahone E, Pritchard A (2015). Test-retest reliability of the Capute scales for neurodevelopmental screening of a high risk sample: Impact of test-retest interval and degree of neonatal risk. J Neonatal Perinatal Med. 8(3), 233-41.